Miltenyi Biotec
Miltenyi Biotec home - back to start page
Miltenyi Biotec
  • MACS® Cell Analysis
Miltenyi Biotec
Miltenyi Biotec
Miltenyi Biotec
Miltenyi Biotec
CliniMACS® Prodigy CliniMACS® Prodigy
CliniMACS® Cell Separation System CliniMACS® Cell Separation System
TheraSorb™ Therapeutic Apheresis TheraSorb™ Therapeutic Apheresis
CryoMACS® Freezing Bags CryoMACS® Freezing Bags
MACS® GMP Products MACS® GMP Products
  MACS GMP Antibodies
  MACS GMP Antigens
  MACS GMP Cytokines
  MACS GMP Cell Culture Media
  MACS GMP Cell Culture Bags
  Apoptotic cell removal
  MACS GMP Certificates
Miltenyi Biotec
MACS eNews
Subscribe to our
MACS eNews
for regular product information via e-mail.
Miltenyi Biotec
MACS® GMP PepTivator® EBV EBNA-1
Overview
MACS GMP PepTivator EBV EBNA-1 is a peptide pool that consists mainly of 15-mer peptides with 11 amino acids overlap. It has been developed for efficient in vitro stimulation and subsequent isolation of EBV EBNA-1–specific CD4+ and CD8+ T cells.
Details
Background information
Epstein-Barr virus (EBV) is a human γ-herpesvirus with B cell growth–transforming ability and carcinogenic potential. More than 90% of human adults are infected with EBV. In healthy individuals, EBV typically establishes a persistent latent infection, in which the virus can be detected in resting, non-proliferating peripheral B lymphocytes.

The Epstein-Barr nuclear antigen 1 (EBNA-1) protein is involved in the replication of viral episomes and therefore crucial for the persistence of the infection. Its expression is maintained in all latency cycles of infection and in all EBV-associated malignancies.


Applications

T cells are essential for the control of the outgrowth of EBV-infected B cells. EBNA-1–specific CD4+ and CD8+ T cells have been found in EBV-infected individuals.1–7

Adoptive transfer of EBNA-1–specific T cells may be an effective tool for the treatment of EBV-associated malignancies.

In vitro stimulation of EBNA-1–specific CD4+ and CD8+ T cells with MACS GMP PepTivator EBV EBNA-1 causes the production of the effector cytokine IFN-γ. The secretion of IFN-γ then permits the enrichment of EBNA-1–specific effector/memory T cells using the CliniMACS® Cytokine Capture System (IFN-gamma).

Quality statement
MACS GMP Products are manufactured and tested under a certified ISO 9001 quality system and in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials.

No animal-, human-, or virus-derived materials were used for manufacture of these products.
Disclaimer
MACS GMP Products are for research use and ex vivo cell culture processing only, and are not intended for human in vivo applications.
 
Miltenyi Biotec
Search this website
Advanced search
Toolbox
Customer login
Contact
Newsletter
Help
Favorites / Prices
Request prices or add products to your favorite list.
Details
Products
MACS GMP PepTivator EBV EBNA-1
Availability: Worldwide (1)
- 60 nmol/peptide for the stimulation of 109 cells
Download datasheet
170-076-129
Qty.:
 

(1) For availability in your country please contact your local representative.
Related products
MACS® GMP PepTivator® EBV LMP2A
MACS® GMP PepTivator® EBV BZLF1
MACS® GMP PepTivator® HCMV pp65
MACS® GMP PepTivator® AdV5 Hexon
CliniMACS® Cytokine Capture System (IFN-gamma) - Product Line
References
1. Blake et al. (2000) J. Immunol. 165: 7078–7087.
2. Khanna et al. (1995) Virology 214: 633–637.
3. Paludan et al. (2002) J. Immunol. 169: 1593–1603.
4. Leen et al. (2001) J. Virol. 75: 8649–8659.
5. Voo et al. (2004) J. Exp. Med. 199: 459–470.
6. Voo et al. (2002) Cancer Res. 62: 7195–7199.
7. Long et al. (2005) J. Virol. 79: 4896–4907.
© 1999 - 2012 Miltenyi Biotec ¦ Terms & conditions ¦ Legal notes
Miltenyi Biotec website